NEJM PISCES Trial: High-Dose Omega-3 Cuts CV Risk 43% | Canchem
This article reviews the PISCES clinical trial published in NEJM and its implications for omega-3 supplementation. For Canchem’s algae-derived and fish oil omega-3 product lines, visit our Products Catalog.
In the world of health supplements, fish oil (omega-3) has always been one of the most discussed—and debated—ingredients. With so many conflicting claims, consumers often struggle to know what to believe.
In November 2025, the world’s most prestigious medical journal, The New England Journal of Medicine (NEJM), published a landmark study called PISCES. This large-scale clinical trial delivers the most compelling evidence to date for omega-3’s cardiovascular protective power.
Even if you are not a dialysis patient, the truths this study reveals about omega-3 dosage and safety are invaluable for anyone who cares about their health.
Why the PISCES Study Is a Game-Changer
For patients undergoing hemodialysis, cardiovascular disease is the leading cause of death—with a mortality rate 20 times that of the general population. For years, the medical community has debated whether fish oil supplementation can meaningfully improve survival.
To settle this question, a research team from Canada and Australia conducted a rigorous,3.5-year randomized controlled trial. They enrolled 1,228 dialysis patients and split them into two groups: one received4grams of fish oil daily, while the other received a corn oil placebo.
The treatment group consumed 4 g of fish oil per day, delivering a total of 2.4 g of pure omega-3 (1.6 g EPA + 0.8 g DHA). This confirms that high concentration is the key to unlocking cardiovascular protection.
Critical Dosage Revealed
Key Data: Comprehensive Cardiovascular Protection
The results electrified the medical community. Compared to the placebo group, patients taking high-dose fish oil showed remarkable protective benefits across every key metric:
↓43%
↓ 63%
Stroke Incidence
↓ 44%
Myocardial Infarction
↓ 43%
Vascular Occlusion Leading to Amputation
| Outcome Measure | Risk Reduction vs. Placebo |
|---|---|
| Major Cardiovascular Events | ↓ 43% (Primary Endpoint) |
| Stroke Incidence | ↓ 63% |
| Myocardial Infarction | ↓ 44% |
| Vascular Occlusion → Amputation | ↓ 43% |
Safety Evidence: Debunking the “Fish Oil Causes Bleeding” Myth
Many people—including some healthcare professionals—worry that high-dose fish oil may impair coagulation and increase bleeding risk. The PISCES study definitively debunks this myth.
4.8%
Serious Bleeding Rate — Fish Oil Group
7.6%
Serious Bleeding Rate — Placebo Group (Higher!)
The placebo group actually experienced a higher rate of serious bleeding than the fish oil group. This proves that under proper monitoring, high-quality fish oil demonstrates excellent safety—consumers need not panic.
3Golden Takeaways for Consumers
While PISCES focused on dialysis patients, the selection logic hidden within its findings applies to every health-conscious consumer:
The trial proved that 2.4 g of omega-3 per day delivers significant results. Most low-concentration fish oil products on the market fall far short of this threshold. Choosing a high-concentration product is simply more efficient.
The study used1.6 g EPA combined with 0.8 g DHA. This confirms that consuming both fatty acids simultaneously provides the most comprehensive, synergistic cardiovascular protection. Neither alone is sufficient.
Supplements should never be taken just for peace of mind. Choose ingredients, concentrations, and forms backed by large-scale clinical evidence—that’s the only way to ensure your money is well spent.
This article is for educational and informational purposes only. If you have specific health conditions, please consult a qualified healthcare professional before supplementation.
Disclaimer
Interested in Learning More?
Contact our team for technical specifications, sampling, or partnership inquiries.